Brittany Stuart, PA
Physician Assistant · Brooklyn, NYNPI 1184366098
Payments from drug & device makers
Across 338 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- AstraZeneca$970
- Alnylam Pharmaceuticals Inc.$929
- MDD US Operations, LLC$828
- Teva Pharmaceuticals USA, Inc.$639
- Biogen$517
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$1472%
- Travel & lodging$7738%
- Food & beverage$8,24390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $1,098 |
| AstraZeneca(2 entities) | 23 | $970 |
| Alnylam Pharmaceuticals Inc. | 39 | $929 |
| MDD US Operations, LLC | 34 | $828 |
| Teva Pharmaceuticals USA, Inc. | 28 | $639 |
| Biogen | 33 | $517 |
| Grifols USA, LLC | 23 | $496 |
| AbbVie | 22 | $474 |
| Otsuka America Pharmaceutical, Inc. | 18 | $442 |
| Xeris Pharmaceuticals, Inc. | 19 | $403 |
| SK Life Science, Inc. | 16 | $355 |
| Eisai Inc. | 18 | $321 |
| Amneal Pharmaceuticals LLC | 5 | $209 |
| Acadia Pharmaceuticals Inc | 8 | $200 |
| Argenx US, Inc. | 6 | $159 |
| Merz Pharmaceuticals, LLC | 5 | $159 |
| Amgen | 2 | $131 |
| Inspire Medical Systems, Inc. | 1 | $104 |
| UCB, Inc. | 4 | $95 |
| Neurelis, Inc. | 3 | $83 |
| Lundbeck LLC | 3 | $77 |
| EMD Serono, Inc. | 2 | $74 |
| Sanofi | 1 | $66 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Pfizer | 2 | $48 |
| Genentech USA, Inc. | 1 | $32 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Life Molecular Imaging Ltd | 1 | $25 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| CSL Behring | 1 | $21 |
| Medtronic | 1 | $21 |
| Octapharma USA, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,163 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AmvuttraVutrisiran Sodium | 16 | $1,915,989 |
| NuplazidPimavanserin Tartrate | 36 | $294,543 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 16 | $206,178 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $105,732 |
| RytaryCarbidopa/Levodopa | 47 | $53,173 |
| NeuproRotigotine | 35 | $39,257 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $31,775 |
| Austedo XrDeutetrabenazine | 12 | $28,814 |
| NamzaricMemantine Hcl/Donepezil Hcl | 14 | $21,806 |
| OngentysOpicapone | 11 | $17,275 |
| Memantine Hcl ErMemantine Hcl | 74 | $12,661 |
| Emgality PenGalcanezumab-Gnlm | 16 | $12,417 |
| Ajovy SyringeFremanezumab-Vfrm | 16 | $11,717 |
| Doxepin Hcl | 70 | $9,214 |
| Ropinirole ErRopinirole Hcl | 41 | $7,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alnylam Pharmaceuticals Inc.Amvuttra | $929 | $1,915,98916 claims |
| Acadia Pharmaceuticals IncNuplazid | $200 | $294,54336 claims |
| PfizerPanzyga | $48 | $206,17816 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $209 | $54,38363 claims |
| UCB, Inc.Neupro | $95 | $39,25735 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $639 | $28,81412 claims |
| AbbVieNamzaric | $474 | $21,80614 claims |
| Neurocrine Biosciences, Inc.Ongentys | $29 | $17,27511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Brooklyn
- Kaitlyn NelsonBrooklyn$289K
- Melissa VelezBrooklyn$68K
- Steven KongBrooklyn$66K
- Hong ChenBrooklyn$57K
- Lindsey AxtBrooklyn$52K
- Gregory CelestinBrooklyn$41K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.